More than 600,000 Medicare beneficiaries have signed up for GLP-1 weight-loss medications in the first two months of a new federal program that caps patient costs at $50 per month, Centers for Medicare & Medicaid Services (CMS) Administrator Dr. These obesity treatments have historically been out of reach for many seniors because of their high price tags. "The biggest thing this program is doing for seniors is turning access to these drugs from a potentially enormous expense into a predictable $50 monthly decision," Michael Ryan, a finance expert and the founder of MichaelRyanMoney.com, told Newsweek.
"Getting 600,000 people enrolled in just two months tells you there was substantial demand." GLP-1 medications such as Wegovy and Zepbound have transformed obesity treatment in recent years, but their high costs have limited access for many Americans, including for retirees living on fixed incomes. Before the new program, patients often faced out-of-pocket expenses that could exceed $1,000 per month. But the new enrollment figures suggest there’s strong demand among older Americans for low-cost GLP-1s, potentially impacting Medicare’s healthcare costs in the long run.
On Monday, Oz said approximately 600,000 seniors have already enrolled in the Medicare GLP-1 Bridge program during its first two months. The initiative launched on July 1 and is scheduled to run through December 31, 2027. Under the program, eligible beneficiaries can receive covered GLP-1 medications for a flat $50 monthly copayment.
The program covers select GLP-1 medications, including Wegovy, Eli Lilly's Zepbound in its KwikPen form, and Foundayo, an oral GLP-1 treatment. However, the program is temporary. "The long term issue is what happens after people build their health and household budgets around that access.
This isn't permanent coverage," Ryan said. "If Medicare ultimately incorporates comparable GLP-1 coverage into Part D, the Bridge may prove to be exactly what its name suggests. A temporary path to something more durable.
If it doesn't, seniors who became accustomed to paying $50 could suddenly face much higher costs or difficult coverage decisions." The Medicare GLP-1 Bridge is a temporary CMS program created to expand access to obesity medications for eligible Medicare beneficiaries. The agency announced the initiative in May, positioning it as a way to provide innovative but costly treatments at a predictable monthly cost while evaluating how broader coverage could affect health outcomes and Medicare spending. Department of Health and Human Services, in a statement.
Extract — continue reading at the source.
